Position in BCYC
as of Mar 31, 2026
· filed May 6, 2026
Position Value
$19,571
-$6,115 QoQ
Shares Held
4,218
+16.3% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BCYC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ASSETMARK, INC holds $266,175,627 across 93 Biotechnology names. BCYC ranks #53 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
3,388,920 | $145,350,778 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
59,954 | $26,771,859 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
166,617 | $10,768,456 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
12,316 | $9,515,834 | |
| 5 | ONC |
BeOne Medicines Ltd.
|
29,569 | $8,781,105 | |
| 6 | ARGX |
Argenx SE
|
9,275 | $6,773,068 | |
| 7 | GMAB |
Genmab A/S
|
224,144 | $6,013,783 | |
| 8 | INSM |
INSMED Inc
|
34,258 | $5,601,868 |
All Filings in BCYC
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $19,571 | 4,218 | Shares | Sole | 2026-05-06 | |
| 2025-12-31 | $25,686 | 3,628 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $28,057 | 3,625 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $14,407 | 2,073 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $10,884 | 1,282 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $17,640 | 1,260 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $34,374 | 1,519 | Shares | Sole | 2024-11-01 | |
| No filing history on record for this holder in this stock. | ||||||